Krystal Biotech, Inc.
KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treatiā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$347.00
Price+0.42%
$1.45
1Y
Price
Market Cap
$10.229b
Large
Price/Earnings 3y Avg5y Avg
43.5x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+55.4%
EBITDA Margin+45.9%
Net Profit Margin+59.7%
Free Cash Flow Margin+55.4%
EBITDA Margin+45.9%
Net Profit Margin+59.7%
Free Cash Flow MarginRevenue
$440.484m
+13.2%
1y CAGR+173.4%
3y CAGR+130.0%
5y CAGREarnings
$241.465m
+17.9%
1y CAGR+287.7%
3y CAGR+242.8%
5y CAGREPS
$7.98
+16.7%
1y CAGR+271.3%
3y CAGR+230.3%
5y CAGRBook Value
$1.359b
$1.501b
Assets$141.522m
Liabilities$8.853m
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
$257.782m
+36.5%
1y CAGR+104.5%
3y CAGR+87.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company